Title
Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to decrease by 65.16%, and institutional views are bullishAbstract
Nektar Therapeutics will report quarterly results on March 12, 2026 Post Market; investors are watching a revenue mix still dominated by royalty-related income, alongside forecasts pointing to a smaller top line and a slightly improved per-share loss compared with the year-ago period.Market Forecast
Based on current-quarter forecasts, Nektar Therapeutics is expected to deliver revenue of 10.40 million, implying a 65.16% year-over-year decline, with EBIT at -40.24 million (down 26.12% year-over-year) and an estimated EPS of -2.47, reflecting a 1.97% year-over-year improvement; no formal guidance was available for gross profit margin or net income. The revenue mix is anticipated to remain skewed toward non-cash royalties linked to the sale of future royalties, with a small contribution from licenses, collaboration, and other income; the company’s profitability profile remains most sensitive to operating expense levels rather than gross margin variability. The most promising near- to medium-term growth vector remains the company’s late-stage pipeline led by rezpegaldesleukin, which currently contributes negligible revenue while management advances clinical programs; the aggregate revenue base last quarter was 11.79 million, down 51.13% year-over-year at the consolidated level.Last Quarter Review
Nektar Therapeutics reported last-quarter revenue of 11.79 million, a gross profit margin of 100.00%, a GAAP net loss attributable to shareholders of -35.52 million, and a quarter-on-quarter improvement in net loss of 14.60%; net profit margin was not disclosed, while EPS came in at -1.87, a 30.74% year-over-year improvement. A key feature of the quarter was continued expense discipline that helped narrow losses year-over-year at the per-share level despite the smaller revenue base. Main business activity remained concentrated in non-cash royalty revenue related to the sale of future royalties at 11.49 million (approximately 97% of total revenue), complemented by licenses, collaboration and other income of 0.30 million; total revenue decreased 51.13% year-over-year, underscoring the volatility inherent in royalty and collaboration inflows.Current Quarter Outlook
Main business: royalty-related income and collaboration inflows
The company’s core reported revenue continues to derive from non-cash royalties arising from a prior monetization of future royalty streams, supplemented by smaller licenses, collaboration, and other revenues. For the current reporting period, the revenue estimate is 10.40 million, a sequential step down from 11.79 million last quarter and a 65.16% year-over-year contraction, indicating that variability in underlying royalty accounting and limited new license milestones will likely constrain the top line. Gross margin, at 100.00% last quarter, is not a relevant swing factor given the non-cash royalty mix; instead, the trajectory of operating expenses will determine the loss profile. The EBIT estimate at -40.24 million implies a deeper operating loss than the prior quarter’s -31.67 million actual result, pointing to higher R&D and clinical execution costs in the period under review. While this combination may still translate into a wider GAAP net loss than in the immediately preceding quarter, the forecasted EPS of -2.47 suggests only a modest year-over-year improvement of 1.97%, reflecting both cost controls and share-count dynamics following recent capital activities.Given the revenue’s dependence on non-cash royalties, investors should focus on the stability and accounting of that stream and on any incremental collaboration receipts. In the prior quarter, non-cash royalties contributed 11.49 million out of 11.79 million in total revenue, implying a heavy concentration that can amplify quarter-to-quarter swings. The guidance bands are not provided, but the revenue and EBIT estimates implicitly assume continued dominance of the royalty component and a lack of significant new collaboration milestones in the period.
Most promising business: rezpegaldesleukin clinical program and value inflection
Nektar Therapeutics’ most promising growth driver is its rezpegaldesleukin program, which recently reported additional clinical readouts in atopic dermatitis during mid-February. While rezpegaldesleukin contributes negligible revenue today, the data update underscores a potential value inflection path if future registrational plans advance on schedule; this is particularly relevant for sentiment around the company’s long-term earnings power rather than near-term revenue. The company’s capital allocation during the quarter appears aligned with pushing this program forward, which helps explain the higher forecasted operating loss (EBIT -40.24 million) as clinical expenses ramp. From a modeling standpoint, near-term P&L pressure is a trade-off for preserving or accelerating timelines, and the market’s expectation for a slightly better year-over-year EPS outcome (+1.97%) suggests that dilution-adjusted performance could be stabilizing even as operating spend rises.Investors will look for any incremental disclosures on study design, regulatory interactions, or partnership prospects for rezpegaldesleukin. Positive communication here can offset the headline impact of a lower revenue print by improving visibility on future non-dilutive funding options and potential milestone structures. In the last quarter, the company’s overall revenue fell 51.13% year-over-year to 11.79 million, so narrative support from clinical progress is central to shaping expectations for the remainder of the year.
Key stock price drivers this quarter: capital raise, cash runway, and expense trajectory
Share performance into and after this report will likely be driven by the interplay between the newly completed equity financing, implied cash runway, and the spending profile embedded in the EBIT forecast. In February, Nektar Therapeutics priced a public offering that was subsequently upsized and closed, raising approximately 460.00 million in gross proceeds; this meaningfully improves liquidity and provides funding flexibility for late-stage clinical plans. Markets typically reward greater balance sheet visibility in development-stage biopharma, and the capital raise can buffer concerns about the capacity to complete key studies without near-term financing risk.At the same time, the forecasted operating loss of -40.24 million highlights an expectation for elevated R&D outlays in the period; investors will watch carefully how actual operating expenses compare with the implicit run rate. Any downside surprise to spending could support a narrower loss than forecast and help reconcile the 1.97% year-over-year EPS improvement with a lower top line. Conversely, if expenses track above the implied run rate, the gap to the EPS estimate might widen despite revenue being close to the 10.40 million forecast. Given the last quarter’s 100.00% gross margin and heavy reliance on non-cash royalty accounting, the operating line remains the primary lever for earnings variability.
Analyst Opinions
Within the collection window from January 1, 2026 to March 5, 2026, the analyst view set is unanimously bullish (2 bullish, 0 bearish). On February 23, 2026, B. Riley raised its price target on Nektar Therapeutics to 150 and reaffirmed a Buy rating, citing strengthened conviction into upcoming clinical and corporate catalysts; the target hike signals increased confidence in value creation potential despite near-term revenue compression. In early March 2026, BTIG reiterated its Buy rating and set a price target of 151, underscoring continued support for the company’s late-stage program and improved capital position following the February financing. The concentration of Buy ratings and the recent upward revision in target price by a well-followed brokerage suggest that institutional investors are prepared to look through a smaller revenue base this quarter, provided management maintains clinical momentum and demonstrates disciplined capital deployment in line with the EBIT and EPS trajectories discussed above.The bullish consensus hinges on a few operational pillars evident in current estimates and recent developments. First, while revenue is forecast at 10.40 million, down 65.16% year-over-year, analysts appear more focused on catalysts and spend efficiency than on top-line fluctuations driven by non-cash royalties. Second, the forecasted EBIT of -40.24 million aligns with the expectation for active clinical execution; if actual spending is well-contained and supports a modest year-over-year improvement in EPS of 1.97%, the path to a lower cash burn trajectory in subsequent quarters becomes more credible. Third, the February equity raise of approximately 460.00 million extends runway and reduces financing overhang, enabling the company to pursue rezpegaldesleukin development at scale without near-term capital constraints, a key point of emphasis in positive rating reiterations.
In sum, the majority analyst perspective remains that this print will be judged less on revenue, which is expected to be 10.40 million, and more on signals around expense discipline, cash runway sufficiency post-raise, and the cadence of rezpegaldesleukin milestones. If management delivers on these qualitative markers while tracking to the EPS estimate of -2.47 and containing operating losses near the -40.24 million forecast, the bullish narrative is likely to persist, consistent with the latest target moves and rating confirmations.
Comments